Seagen:Tuksya combo with Kadcyla helps PFS in patients with treated HER2 MBC

Seagen announced data from the Phase 3 HER2CLIMB-02 clinical trial of TUKYSA or tucatinib in combination with the antibody-drug conjugate ado-trastuzumab emtansine Kadcyla.The combination showed a statistically significant improvement in progression-free survival PFS the study’s primary endpoint, in patients with unresectable locally advanced or metastatic human epidermal growth factor receptor 2-positive breast cancer who had been previously treated with trastuzumab and a taxane, compared to those who received placebo plus ado-trastuzumab emtansine. Discontinuations due to adverse events were more common in the combination arm of the trial, but no new safety signals were observed for the combination. “Combining HER2-directed therapies can improve outcomes for people with locally advanced or metastatic HER2-positive breast cancer,” said lead author Sara A. Hurvitz, M.D., Professor and Head of the Division of Hematology and Oncology at the University of Washington Department of Medicine and Senior Vice President and Director of the Clinical Research Division at Fred Hutchinson Cancer Center. “Notably, the HER2CLIMB-02 trial is the second randomized study including patients with brain metastases demonstrating that TUKYSA delays disease progression in this population.” “The results from the HER2CLIMB-02 study reinforce the clinical activity of TUKYSA in patients with HER2-positive metastatic breast cancer,” said Roger Dansey, M.D., President of Research and Development and Chief Medical Officer at Seagen.